Post-radiation sarcoma: A study by the Eastern Asian Musculoskeletal Oncology Group

Abstract

The oncologic risk of ionizing radiation is widely known. Sarcomas developing after radiotherapy have been reported, and they are a growing problem because rapid advancements in cancer management and screening have increased the number of long-term survivors. Although many patients have undergone radiation treatment in Asian countries, scarce reports on post-radiation sarcomas (PRSs) have been published. We investigated the feature and prognostic factors of PRSs in an Asian population. The Eastern Asian Musculoskeletal Oncology Group participated in this project. Cases obtained from 10 centers were retrospectively reviewed. Patients with genetic malignancy predisposition syndrome, or who had more than one type of malignancy before the development of secondary sarcoma were excluded. Forty-two high-grade sarcomas among a total of 43 PRSs were analyzed. There were 29 females and 13 males, with a median age of 58.5 years; 23 patients had bone tumors and 19 had soft tissue tumors. The most common primary lesion was breast cancer. The median latency period was 192 months. There were no differences in radiation dose, latency time, and survival rates between bone and soft tissue PRSs. The most common site and diagnosis were the pelvic area and osteosarcoma and malignant fibrous histiocytoma for bone and soft tissue PRSs. The median follow-up period was 25.5 months. Five-year metastasis-free and overall survival rates were 14.5% and 16.6%, and 39.1% and 49.6% for bone and soft tissue PRSs. Survival differences depending on initial metastasis and surgery were significant in soft tissue sarcomas. Although this study failed to find ethnic differences, it is the largest review on PRS in an Asian population. As early recognition through long-term surveillance is a key to optimal management, clinicians should take efforts to understand the real status of PRS.

A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy

“…In the current study, the authors found that the most common primary malignancies were carcinomas, followed by sarcomas and lymphomas/leukemias. These results were inconsistent with previous studies 27 , 28 . Distant metastases were present at diagnosis in 21.6% of secondary osteosarcoma patients.…”

Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions - Part I. Ablation

“…10,11 All of these may arise in the MSK system and are considered primary tumors if arising within one of the main structures (e.g., muscle, fat, fibrous layers and fascia, vessels, or nerves) or secondary if they are metastatic or arise as sarcomas in cancer survivors. 12,13 Although benign tumors have lower morbidity and much lower mortality compared with malignant tumors, consistently applying similar fundamental oncologic principles when managing secondary pathologic fractures remains critical to improving clinical outcomes. 1 Failure to identify and consider biological behaviors of such tumors can result in inappropriate surgical or interventional strategies, use of unsuitable surgical implants, and increased morbidity/mortality rates, both in childhood as well as later in life.…”

Secondary Malignancy in Giant Cell Tumor: A Single-Center Study

“…Although radiotherapy is known to induce malignant tumors 22,23 and most secondary MGCT cases developed after radiation treatment in previous studies 10 , none of the cases in this study were associated with radiation treatment. Currently, limited radiotherapy data are available for benign GCTB 11 because the treatment is indicated for locations where curative surgery is unfeasible, such as the spine or sacrum, or for aggressive or recurrent tumors 23 .…”

“…However, the preference has declined lately 8 . In contrast to ndings from the Western countries, radiotherapy does not appear to be readily used for managing post-radiation sarcomas in Asian populations 22 .…”